💊 Is BA.2 worse? Some say yes. Others say no; Moderna enters the RSV queue; the US FDA gets busy

Feb 23, 2022

∙ Paid

In today’s Kable: Homology goes where BioMarin did; Moderna goes where many others did; BioNTech gets into oncology; Lilly goes big on gene therapies; GSK unveils Haleon; Iran returns vaccine doses; Evidence mounting that BA.2 is bad. Or not.

Keep reading with a 7-day free trial

Subscribe to The Kable to keep reading this post and get 7 days of free access to the full post archives.